ProKidney Corp. is a clinical-stage biotechnology company, which engages in the development of a proprietary cell therapy platform. The company is headquartered in Winston-Salem, North Carolina and currently employs 204 full-time employees. The company went IPO on 2021-06-30. The firm is focused on cell therapy platforms capable of treating multiple chronic kidney diseases (CKD) using a patient’s own cells isolated from the patient intended for treatment. The Company’s lead product candidate, rilparencel, is designed to preserve kidney function in a CKD patient’s diseased kidneys. Rilparencel is a product that includes autologous selected renal cells (SRCs) prepared from a patient’s own (autologous) kidney cells. Rilparencel is an investigational product that includes a mixture of kidney cells prepared from the participant’s own kidney tissue. The SRC are formulated rilparencel for reinjection into the patient’s kidneys using a minimally invasive outpatient procedure that is repeatable, if necessary. The company is conducting a global Phase III development program and multiple Phase II clinical trials for rilparencel in subjects with moderate to severe CKD and diabetes.
Follow-Up Questions
¿Quién es el CEO de ProKidney Corp?
Dr. Bruce Culleton es el Chief Executive Officer de ProKidney Corp, se unió a la empresa desde 2023.
¿Qué tal es el rendimiento del precio de la acción PROK?
El precio actual de PROK es de $2.75, ha increased un 2.79% en el último día de negociación.
¿Cuáles son los temas de negocio principales o las industrias de ProKidney Corp?
ProKidney Corp pertenece a la industria Biotechnology y el sector es Health Care
¿Cuál es la capitalización bursátil de ProKidney Corp?
La capitalización bursátil actual de ProKidney Corp es $810.7M
¿Es ProKidney Corp una compra, una venta o una posición de mantener?
Según los analistas de Wall Street, 8 analistas han realizado calificaciones de análisis para ProKidney Corp, incluyendo 5 fuerte compra, 4 compra, 4 mantener, 1 venta, y 5 fuerte venta
